Drugs / GH21
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05183243 | Feb 2022 → Dec 2024 | colorectal cancer, head and neck neoplasm, malignant pancreatic neoplasm, non-small cell lung carcinoma | Suzhou Genhouse Bio Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07446725 | Feb 2026 → Oct 2029 expected | — | Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06435455 | Jul 2024 → Sep 2027 expected | — | Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06306456 | Mar 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Suzhou Genhouse Bio Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07318649 | Dec 2025 → Dec 2026 expected | — | Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06322095 | Mar 2024 → Sep 2025 | — | Suzhou Genhouse Bio Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GH21 | “GH21 Capsule is a potent, orally active human SHP2 allosteric inhibitor.” NCT07446725 ↗ |
| Action | Inhibit | “GH21 Capsule is a potent, orally active human SHP2 allosteric inhibitor.” NCT07446725 ↗ |
| Route | Oral | “GH21 for oral administration” NCT05183243 ↗ |